{
    "nct_id": "NCT03662542",
    "official_title": "A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis",
    "inclusion_criteria": "* Confirmed clinical diagnosis of ulcerative colitis (UC) at least 3 months before screening\n* Moderately to severely active UC as defined by Mayo score\n* History of inadequate response to or failure to tolerate conventional therapy\n* Has screening laboratory test results within the study protocol defined parameters\n* A woman of childbearing potential must have a negative highly sensitive serum (beta human chorionic gonadotropin) pregnancy test result at screening and a negative urine pregnancy test result at Week 0\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Has severe extensive colitis as defined in the study protocol\n* Has UC limited to the rectum only or to less than (<) 20 centimeter (cm) of the colon\n* Has a history of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, before screening\n* Has any known malignancy or has a history of malignancy (with the exception of basal cell carcinoma; squamous cell carcinoma in situ of the skin; or cervical carcinoma in situ that has been treated with no evidence of recurrence; or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years before screening)\n* Has known allergies, hypersensitivity, or intolerance to guselkumab or golimumab or their excipients",
    "miscellaneous_criteria": ""
}